Empaglinna Tablet 10/5 mg (Empagliflozin 2L-Proline, Linagliptin)
Empagliflozin 2L-Proline 15.107mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
MFDS item code 202502558 · Approved 2025.09.26
Improvement of blood glucose control in patients with type 2 diabetes
This medication is used to help improve blood sugar control in patients with type 2 diabetes when combined with dietary and exercise regimens. The combination of empagliflozin and linagliptin helps to stabilize blood sugar levels. Therefore, taking this medication will greatly assist you in improving blood sugar control.
The recommended starting dose is empagliflozin 10 mg (equivalent to 15.107mg of empagliflozin 2L-proline)/linagliptin 5 mg once daily. For patients who tolerate empagliflozin 10 mg/linagliptin 5 mg and require additional glycemic control, the dose of this medicine may be increased to 25/5 mg (equivalent to 37.766mg of empagliflozin 2L-proline) once daily. Patients switching to this medicine from concomitant empagliflozin and linagliptin therapy should receive their previous doses. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dosage adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or greater. No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in these patients. No dosage adjustment based on age is necessary. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication is a combination of two active ingredients, empagliflozin and linagliptin. It should not be used in certain patients. For example, it is contraindicated in those with an allergy to any component of this medication, patients with type 1 diabetes, diabetic ketoacidosis, and those undergoing dialysis. Caution is required when using this medication in patients with impaired kidney function or heart failure. Since kidney function is related to the effectiveness of this medication, it is important to regularly monitor kidney function before and during treatment. Rare skin conditions such as acute pancreatitis or bullous pemphigoid may occur while taking this medication; therefore, if you experience abdominal pain or develop blisters on the skin, you should consult a doctor immediately. The most common side effect reported is urinary tract infection, and other side effects such as hypoglycemia, ketoacidosis, and hypersensitivity reactions have also been reported. The risk of hypoglycemia may increase when used in conjunction with insulin or sulfonylureas. This medication helps control blood sugar, but a serious condition called ketoacidosis may occur; if symptoms such as nausea, vomiting, abdominal pain, or breathing difficulties arise, immediate medical attention is critical. Additionally, this medication can cause fluid loss and a drop in blood pressure, so elderly patients or those with low blood pressure should take it with caution. Due to the risk of urinary tract infections and genital fungal infections, prompt treatment is necessary if any infection symptoms develop. Pregnant or breastfeeding women are advised not to take this medication unless in special circumstances. Its safety and efficacy have not been established in children under 18 years old, so it is advisable not to use it in this age group. While taking this medication, you should be mindful of hypoglycemia symptoms when driving or operating machinery, especially when used in combination with insulin or sulfonylureas. In case of overdose, it is important to visit a medical facility immediately for appropriate treatment. Finally, store this medication out of reach of children and keep it in its original container to maintain its safety and quality.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius. This way, the medication's effectiveness can be preserved for a longer period and used safely.
Light yellow triangular film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 2L-Proline 15.107mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Empagliflozin 2L-Proline 15.107mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Empagliflozin 2L-Proline 37.766mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Empagliflozin 2L-Proline 37.766mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.